275 related articles for article (PubMed ID: 32562381)
1. The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis.
Lajczak-McGinley NK; Porru E; Fallon CM; Smyth J; Curley C; McCarron PA; Tambuwala MM; Roda A; Keely SJ
Physiol Rep; 2020 Jun; 8(12):e14456. PubMed ID: 32562381
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon.
Ward JBJ; Lajczak NK; Kelly OB; O'Dwyer AM; Giddam AK; Ní Gabhann J; Franco P; Tambuwala MM; Jefferies CA; Keely S; Roda A; Keely SJ
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G550-G558. PubMed ID: 28360029
[No Abstract] [Full Text] [Related]
3. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis.
Ruiz-Gaspà S; Dubreuil M; Guañabens N; Combalia A; Peris P; Monegal A; Parés A
Eur J Clin Invest; 2014 Dec; 44(12):1206-14. PubMed ID: 25331234
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.
Golden JM; Escobar OH; Nguyen MVL; Mallicote MU; Kavarian P; Frey MR; Gayer CP
Am J Physiol Gastrointest Liver Physiol; 2018 Aug; 315(2):G259-G271. PubMed ID: 29672156
[TBL] [Abstract][Full Text] [Related]
5. The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing.
Mroz MS; Lajczak NK; Goggins BJ; Keely S; Keely SJ
Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G378-G387. PubMed ID: 29351391
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid attenuates colonic epithelial secretory function.
Kelly OB; Mroz MS; Ward JB; Colliva C; Scharl M; Pellicciari R; Gilmer JF; Fallon PG; Hofmann AF; Roda A; Murray FE; Keely SJ
J Physiol; 2013 May; 591(9):2307-18. PubMed ID: 23507881
[TBL] [Abstract][Full Text] [Related]
7. Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.
Loddenkemper C; Keller S; Hanski ML; Cao M; Jahreis G; Stein H; Zeitz M; Hanski C
Int J Cancer; 2006 Jun; 118(11):2750-7. PubMed ID: 16385573
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids.
Zhou C; Wang Y; Li C; Xie Z; Dai L
Microbiol Spectr; 2023 Mar; 11(2):e0333022. PubMed ID: 36943054
[TBL] [Abstract][Full Text] [Related]
9. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
10. The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-κB dependent mechanism in Caco-2 cells.
Yao B; He J; Yin X; Shi Y; Wan J; Tian Z
Toxicol Lett; 2019 Nov; 316():109-118. PubMed ID: 31472180
[TBL] [Abstract][Full Text] [Related]
11. PGI
Pochard C; Gonzales J; Bessard A; Mahe MM; Bourreille A; Cenac N; Jarry A; Coron E; Podevin J; Meurette G; Neunlist M; Rolli-Derkinderen M
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1037-1060. PubMed ID: 33971327
[TBL] [Abstract][Full Text] [Related]
12. Lignans from Schisandra sphenanthera protect against lithocholic acid-induced cholestasis by pregnane X receptor activation in mice.
Fan S; Liu C; Jiang Y; Gao Y; Chen Y; Fu K; Yao X; Huang M; Bi H
J Ethnopharmacol; 2019 Dec; 245():112103. PubMed ID: 31336134
[TBL] [Abstract][Full Text] [Related]
13. Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation.
Mooranian A; Zamani N; Ionescu CM; Takechi R; Luna G; Mikov M; Goločorbin-Kon S; Kovačević B; Al-Salami H
Pharmacol Rep; 2020 Apr; 72(2):368-378. PubMed ID: 32048259
[TBL] [Abstract][Full Text] [Related]
14. The Yin and Yang of bile acid action on tight junctions in a model colonic epithelium.
Sarathy J; Detloff SJ; Ao M; Khan N; French S; Sirajuddin H; Nair T; Rao MC
Physiol Rep; 2017 May; 5(10):e13294. PubMed ID: 28554966
[TBL] [Abstract][Full Text] [Related]
15. Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.
van Gorkom BA; van der Meer R; Boersma-van Ek W; Termont DS; de Vries EG; Kleibeuker JH
Scand J Gastroenterol; 2002 Aug; 37(8):965-71. PubMed ID: 12229974
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters.
Iwaki T; Ishizaki K; Kinoshita S; Tanaka H; Fukunari A; Tsurufuji M; Imada T
World J Gastroenterol; 2007 Oct; 13(37):5003-8. PubMed ID: 17854144
[TBL] [Abstract][Full Text] [Related]
17. Fermented barley and soybean (BS) mixture enhances intestinal barrier function in dextran sulfate sodium (DSS)-induced colitis mouse model.
Woo JK; Choi S; Kang JH; Kim DE; Hurh BS; Jeon JE; Kim SY; Oh SH
BMC Complement Altern Med; 2016 Dec; 16(1):498. PubMed ID: 27912750
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.
Van den Bossche L; Hindryckx P; Devisscher L; Devriese S; Van Welden S; Holvoet T; Vilchez-Vargas R; Vital M; Pieper DH; Vanden Bussche J; Vanhaecke L; Van de Wiele T; De Vos M; Laukens D
Appl Environ Microbiol; 2017 Apr; 83(7):. PubMed ID: 28115375
[TBL] [Abstract][Full Text] [Related]
20. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids.
Stenman LK; Holma R; Eggert A; Korpela R
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G227-34. PubMed ID: 23203158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
